Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and thank you for standing by. Welcome to the Sarepta Therapeutics Second Quarter 2024 Financial Results Conference Call.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 3,000,000 | $474,000,000 | -31% | 6.31% |
| 2. | Farallon Capital Thomas Steyer | 2,295,000 | $362,610,000 | -7% | 1.71% |
| 3. | EcoR1 Capital Oleg Nodelman | 1,407,322 | $222,356,876 | -27% | 6.8% |
| 4. | Casdin Capital Eli Casdin | 1,073,500 | $169,613,000 | +1% | 13% |
| 5. | Citadel Investment Group Ken Griffin | 775,821 | $122,579,718 | -50% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | 284,034 | 2024-08-16 | Filing | ||
| $134.06 | 18,284 | 278,386 | 2024-08-16 | Filing | ||
| $133.07 | 13,106 | 260,102 | 2024-08-16 | Filing | ||
| $78.81 | 40,000 | Director | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | Director | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $164.52 | 2,549 | 17,129 | 2024-06-25 | Filing | ||
| $163.53 | 3,840 | 19,678 | 2024-06-25 | Filing | ||
| $162.65 | 17,581 | 23,518 | 2024-06-25 | Filing | ||
| $161.82 | 4,168 | 41,099 | 2024-06-25 | Filing | ||
| $160.31 | 975 | 45,267 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,816,124 | $850,138,837 | 0.01% | |
| 2. | 6,211,792 | $599,003,103 | 0.01% | |
| 3. | 5,345,785 | $515,482,888 | 0.3% | |
| 4. | 4,741,485 | $457,221,399 | 0.1% | |
| 5. | 4,127,610 | $398,025,433 | 0.07% |
News See All
Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics (SRPT) on X (formerly Twittter) by user quantumup. In this article we will summarize the bulls' thesis on SRPT.
Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?
We recently compiled the list of the 10 Best Fast Growth Stocks To Buy according to the hedge funds using the latest sentiment data.
10 Best Fast Growth Stocks To Buy Now
Growth stocks are those that are either growing their revenue in mid to high double or triple digit percentages or those who trade at significantly higher prices when compared to their earnings.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc.
5 Unstoppable Stocks That Will Make You Richer
In this article, we discuss the 5 unstoppable stocks that will make you richer.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks.
Billionaire Ray Dalio and Insiders Love These 10 Stocks
In this article, we will take a detailed look at Billionaire Ray Dalio and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ray Dalio and Insiders Love...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.47, expectations were $-0.03. Sarepta Therapeutics, Inc.
Billionaire Hedge Funds
